Form 4: Reviva Pharmaceuticals Director Parag Saxena Acquires Stock Options

Director Parag Saxena of Reviva Pharmaceuticals Holdings, Inc. was granted stock options for 8,200 shares on December 10, 2024.

Summary

• Parag Saxena, a director and 10% owner of Reviva Pharmaceuticals Holdings, Inc., was granted stock options to purchase 8,200 shares of common stock.
• The options were granted on December 10, 2024, with an exercise price of $2.52 per share.
• The options vest 100% on the one-year anniversary of the grant date, provided Mr. Saxena remains a director.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The granting of stock options to a director aligns their interests with the company's long-term success.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with shareholders in publicly traded companies.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the pharmaceutical industry and other sectors.
• Vesting schedules, such as the one-year cliff vesting in this case, are typical to ensure continued service and commitment.
• The exercise price being based on the closing price on the grant date is also a standard practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to increased value.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, beneficial ownership, Reviva Pharmaceuticals, RVPH